Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aekkachai Tuekprakhon has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Not All Heroes Wear Capes—Some Just Glow: Exploring Carbon Dots as Nanoagents Against COVID-19

    by Alexandra Karagianni, Adamantia Zourou, Aekkachai Tuekprakhon, Nadiya Boyar, Zania Stamataki, Konstantinos V. Kordatos

    The coronavirus disease (COVID-19) pandemic highlighted critical limitations in ongoing diagnostic and therapeutic strategies, underscoring the urgent need for alternative and complementary approaches. Carbon dots (CDs) represent a novel class of fluorescent carbon-based nanomaterials with increased research interest owing to their enhanced biocompatibility, tunable photoluminescence, aqueous solubility, and rich surface chemistry. This review outlines current approaches in the diagnosis and treatment of COVID-19, along with the main structural, physicochemical, and biological features of CDs. Recent advances in the application of CDs as biosensing and antiviral nanomaterials against SARS-CoV-2 are critically discussed with an emphasis on the influence of synthetic routes, precursor compounds, heteroatom doping, surface functionalization, and purification strategies on their optical behavior and biological performance. CD-based biosensors mainly rely on fluorescence-sensing strategies, exploiting changes in photoluminescence intensity or energy-transfer processes upon recognition of viral targets. Electrochemical approaches are also investigated, highlighting the role of CDs as electrode modifiers to enable sensitive immunodetection in complex biological samples. Apart from diagnosis, the therapeutic potential of CDs is underscored by inhibiting viral entry, replication, disrupting cell membranes, or modulating oxidative stress. Finally, current limitations, challenges, and future perspectives regarding mechanistic understanding, synthesis parameters, biodistribution, and clinical translation are discussed, demonstrating the potential of CDs as novel “shiny weapons” against COVID-19, combining therapeutic and diagnostic functions.

  • Open Access

    Carbon Dots-TiO2 Decorated with Ag Nanoparticles for Efficient Photocatalytic and Antiviral Applications

    by Alexandra Karagianni, Adamantia Zourou, Aekkachai Tuekprakhon, Afroditi Ntziouni, Anna-Maria Tavlaridi, Ioanna Kitsou, Dimitra Katerinopoulou, Aspasia Stoumpidi, Georgios Kiriakidis, Zania Stamataki, et al.

    The modern world is confronting critical environmental and biomedical challenges, underscoring the urgent need for the development of multifunctional materials—an inherently interdisciplinary field, bridging materials science and engineering, environmental science and biomedicine. Titanium dioxide (TiO2) is widely recognized for its photocatalytic and antiviral properties, enabling the degradation of pollutants and mitigation of viral contamination under solar irradiation. Nevertheless, it exhibits certain limitations, such as wide band gap and high recombination rate of photogenerated electron–hole pairs. To address these limitations, TiO2 prepared by a co-precipitation method was modified with N-Doped Carbon Dots (N-CDs) via a hydrothermal treatment, which extend light absorption into the visible region and enhance charge separation. Further functionalization with silver nanoparticles (Ag NPs)—well known for their antimicrobial properties—via a simple thermal process under ambient conditions, introduced additional reactive oxygen species generation, creating a synergistic effect. The as-prepared TiO2, TiO2/N-CDs and TiO2/N-CDs/Ag samples were characterized via several techniques, such as XRD, micro-Raman, FT-IR, TEM and UV-Vis. In addition, their photocatalytic and antiviral activity against methylene blue (MB) and nitrogen oxide (NOx) pollutants, as well as SARS-CoV-2, was evaluated. Based on the results of liquid-phase photocatalysis, TiO2, TiO2/N-CDs and TiO2/N-CDs/Ag presented a degradation efficiency of 78%, 85% and 95%, respectively, whereas different trends were observed under gaseous-phase conditions. The TiO2/N-CDs/Ag hybrid material demonstrated superior antiviral activity against SARS-CoV-2 (IC50: 1.24 ± 0.34 g/L), compared to both TiO2 (IC50: 1.78 ± 0.30 g/L) and TiO2/N-CDs (IC50: >2.5 g/L), highlighting its potential as an effective multifunctional material. Finally, TiO2/N-CDs/Ag was incorporated onto a paper substrate, demonstrating antiviral activity, showing promising scalability for application across a wide range of future substrates. To the best of our knowledge, this is the first study presenting TiO2/N-CDs/Ag with dual photocatalytic and antiviral activity.

  • Open Access

    Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis

    by Sebastian Emmanuel Willyanto, Yohanes Audric Alimsjah, Krisanto Tanjaya, Aekkachai Tuekprakhon, Aulia Rahmi Pawestri

    Relapse/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) represents paediatric cancer with a challenging prognosis. CAR T-cell treatment, considered an advanced treatment, remains controversial due to high relapse rates and adverse events. This study assessed the efficacy and safety of CAR T-cell therapy for r/r B-ALL. The literature search was performed on four databases. Efficacy parameters included minimal residual disease negative complete remission (MRD-CR) and relapse rate (RR). Safety parameters constituted cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Anti-CD22 showed superior efficacy with the highest MRD-CR event rate and lowest RR, compared to anti-CD19. Combining CAR T-cell therapy with haploidentical stem cell transplantation improved RR. Safety-wise, bispecific anti-CD19/22 had the lowest CRS rate, and anti-CD22 showed the fewest ICANS. Analysis of the costimulatory receptors showed that adding CD28ζ to anti-CD19 CAR T-cell demonstrated superior efficacy in reducing relapses with favorable safety profiles. Choosing a more efficacious and safer CAR T-cell treatment is crucial for improving overall survival in acute leukaemia. Beyond the promising anti-CD22 CAR T-cell, exploring costimulatory domains and new CD targets could enhance treatment effectiveness for r/r B-ALL.


  • Open Access

    Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2

    by Manon Ragonnet-Cronin, Rungtiwa Nutalai, Jiandong Huo, Aiste Dijokaite-Guraliuc, Raksha Das, Aekkachai Tuekprakhon, Piyada Supasa, Chang Liu, Muneeswaran Selvaraj, Natalie Groves, et al.

    Summary: Some COVID-19 patients are unable to clear their infection or are at risk of severe disease, requiring treatment with neutralising monoclonal antibodies (nmAb) and/or antivirals. The rapid roll-out of novel therapeutics means there is limited understanding of the likely genetic barrier to drug resistance. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approach to the detection of emerging drug resistance. Here we report the accrual of mutations in Delta and Omicron cases treated with casirivimab+imdevimab and sotrovimab respectively. Mutations occur within the epitopes of the respective nmAbs. For casirivimab+imdevimab these are present on contiguous raw reads, simultaneously affecting both components. Using surface plasmon resonance and pseudoviral neutralisation assays we demonstrate these mutations reduce or completely abrogate antibody affinity and neutralising activity, suggesting they are driven by immune evasion. In addition, we show that some mutations also reduce the neutralising activity of vaccine-induced serum.